Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Home
About
Overview
Open Source Software
Help
History (1)
Improved overall survival in melanoma with combined dabrafenib and trametinib.
See All Pages
Find People
Find Everything
Login
to
edit your profile
(add a photo, education, awards, etc.), search
student opportunities
, and
create reports
.
Edit My Profile
My Person List (
0
)
Opportunity Search
Return to Top
Improved overall survival in melanoma with combined dabrafenib and trametinib.
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015 Jan 01; 372(1):30-9.
View in:
PubMed
subject areas
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Imidazoles
Indoles
Intention to Treat Analysis
Kaplan-Meier Estimate
Male
Melanoma
Middle Aged
Mitogen-Activated Protein Kinase Kinases
Mutation
Oximes
Protein Kinase Inhibitors
Proto-Oncogene Proteins B-raf
Pyridones
Pyrimidinones
Skin Neoplasms
Sulfonamides
Survival Analysis
Young Adult
authors with profiles
Keith Thomas Flaherty, M.D.